Cationic PTD/CPP-mediated macromolecular delivery: Charging into the cell

Expert Opinion on Drug Delivery

Volumn 12, Issue 10, 2015, Pages 1627-1636

  Lönn, Peter ^a,b   Dowdy, Steven F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

CPP; delivery; macromolecular therapeutics; PTD

Indexed keywords

ARGININE; CELL PENETRATING PEPTIDE; OLIGONUCLEOTIDE; PEPTIDE; PROTEIN; CARRIER PROTEIN; CATION; MACROMOLECULE; PENETRATIN; SMALL INTERFERING RNA;

CELL SURFACE; CYTOTOXICITY; DRUG DELIVERY SYSTEM; ENDOCYTOSIS; ENDOSOME; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MACROMOLECULE; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; ADMINISTRATION AND DOSAGE; ANIMAL; CHEMISTRY; HUMAN; METABOLISM; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE;

ANIMALS; CARRIER PROTEINS; CATIONS; CELL-PENETRATING PEPTIDES; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; ENDOSOMES; HUMANS; MACROMOLECULAR SUBSTANCES; PROTEIN STRUCTURE, TERTIARY; RNA, SMALL INTERFERING;

EID: 84942134339     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2015.1046431     Document Type: Review

References (85)

1. Berg A van den, Dowdy SF. Protein transduction domain delivery of therapeutic macromolecules. Curr Opin Biotechnol 2011;22:888-93
2. Belting M, Wittrup A. Developments in macromolecular drug delivery. Methods Mol Biol 2009;480:1-10
3. Lindgren M, Langel U. Classes and prediction of cell-penetrating peptides. Methods Mol Biol 2011;683:3-19
4. Madani F, Lindberg S, Langel U, et al. Mechanisms of cellular uptake of cellpenetrating peptides. J Biophys 2011;2011:414729
5. Koren E, Torchilin VP. Cell-penetrating peptides: breaking through to the other side. Trends Mol Med 2012;18:385-93
6. Heitz F, Morris MC, Divita G. Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br J Pharmacol 2009;157:195-206
7. Johnson RM, Harrison SD, Maclean D. Therapeutic applications of cellpenetrating peptides. Methods Mol Biol 2011;683:535-51
8. Palm-Apergi C, Lonn P, Dowdy SF. Do cell-penetrating peptides actually "penetrate" cellular membranes? Mol Ther 2012;20:695-7
9. Duchardt F, Fotin-MleczekM, Schwarz H, et al. A comprehensive model for the cellular uptake of cationic cell-penetrating peptides. Traffic 2007;8:848-66
10. Green M, Loewenstein PM. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell 1988;55:1179-88
11. Frankel AD, Pabo CO. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 1988;55:1189-93
12. Joliot A, Pernelle C, Deagostini-Bazin H, Prochiantz A. Antennapedia homeobox peptide regulates neural morphogenesis. Proc Natl Acad Sci USA 1991;88:1864-8
13. Fawell S, Seery J, Daikh Y, et al. Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci 1994;91:664-8
14. Ezhevsky SA, Nagahara H, Vocero-Akbani AM, et al. Hypo-phosphorylation of the retinoblastoma protein (pRb) by cyclin D:Cdk4/6 complexes results in active pRb. Proc Natl Acad Sci USA 1997;94:10699-704
15. Vives E, Brodin P, Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 1997;272:16010-17
16. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 1999;285:1569-72
17. Glogau R, Blitzer A, Brandt F, et al. Results of a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a botulinum toxin type A topical gel for the treatment of moderate-to-severe lateral canthal lines. J Drugs Dermatol 2012;11:38-45
18. Amand HL, Fant K, Norden B, Esbjorner EK. Stimulated endocytosis in penetratin uptake: effect of arginine and lysine. Biochem Biophys Res Commun 2008;371:621-5
19. Amand HL, Rydberg HA, Fornander LH, et al. Cell surface binding and uptake of arginine-and lysine-rich penetratin peptides in absence and presence of proteoglycans. Biochim Biophys Acta 2012;1818:2669-78
20. Rydberg HA, Matson M, Amand HL, et al. Effects of tryptophan content and backbone spacing on the uptake efficiency of cell-penetrating peptides. Biochemistry 2012;51:5531-9
21. Nakase I, Tadokoro A, Kawabata N, et al. Interaction of arginine-rich peptides with membrane-associated proteoglycans is crucial for induction of actin organization and macropinocytosis. Biochemistry 2007;46:492-501
22. Takayama K, Nakase I, Michiue H, et al. Enhanced intracellular delivery using arginine-rich peptides by the addition of penetration accelerating sequences (Pas). J Control Release 2009;138:128-33
23. Takayama K, Hirose H, Tanaka G, et al. Effect of the attachment of a penetration accelerating sequence and the influence of hydrophobicity on octaargininemediated intracellular delivery. Mol Pharm 2012;9:1222-30
24. Wadia JS, Stan R V, Dowdy SF. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med 2004;10:310-15
25. Kaplan IM, Wadia JS, Dowdy SF. Cationic TAT peptide transduction domain enters cells by macropinocytosis. J Control Release 2005;102:247-53
26. Nakase I, Niwa M, Takeuchi T, et al. Cellular uptake of arginine-rich peptides: roles for macropinocytosis and actin rearrangement. Mol Ther 2004;10:1011-22
27. Sorkin A, Zastrow M Von. Signal transduction and endocytosis: close encounters of many kinds. Nat Rev Mol Cell Biol 2002;3:600-14
28. Roy C Le, Wrana JL. Clathrin-and non-clathrin-mediated endocytic regulation of cell signalling. Nat Rev Mol Cell Biol 2005;6:112-26
29. Doherty GJ, McMahon HT. Mechanisms of endocytosis. Annu Rev Biochem 2009;78:857-902
30. Gump JM, June RK, Dowdy SF. Revised role of glycosaminoglycans in TAT protein transduction domain-mediated cellular transduction. J Biol Chem 2010;285:1500-7
31. Rusnati M, Coltrini D, Oreste P, et al. Interaction of HIV-1 Tat protein with heparin. Role of the backbone structure, sulfation, and size. J Biol Chem 1997;272:11313-20
32. Console S, Marty C, Garća-Echeverŕa C, et al. Antennapedia and HIV transactivator of transcription (TAT) "protein transduction domains" promote endocytosis of high molecular weight cargo upon binding to cell surface glycosaminoglycans. J Biol Chem 2003;278:35109-14
33. Letoha T, Keller-Pinter A, Kusz E, et al. Cell-penetrating peptide exploited syndecans. Biochim Biophys Acta 2010;1798:2258-65
34. Nakase I, Osaki K, Tanaka G, et al. Molecular interplays involved in the cellular uptake of octaarginine on cell surfaces and the importance of syndecan-4 cytoplasmic V domain for the activation of protein kinase Ca. Biochem Biophys Res Commun 2014;446:857-62
35. Rothbard JB, Jessop TC, Lewis RS, et al. Role of membrane potential and hydrogen bonding in the mechanism of translocation of guanidinium-rich peptides into cells. J Am Chem Soc 2004;126:9506-7
36. Vives E, Schmidt J, Pelegrin A. Cell-penetrating and cell-targeting peptides in drug delivery. Biochim Biophys Acta 2008;1786:126-38
37. Teesalu T, Sugahara KN, Ruoslahti E. Tumor-penetrating peptides. Front Oncol 2013;3:216
38. Pasqualini R, Koivunen E, Ruoslahti E. Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol 1997;15:542-6
39. Lundberg M, Johansson M. Positively charged DNA-binding proteins cause apparent cell membrane translocation. Biochem Biophys Res Commun 2002;291:367-71
40. Lonn P, Dowdy SF. 14. From bench to bedside: cationic TAT peptide transduction domain enters cells by macropinocytosis (2005): Original research article: Cationic TAT peptide transduction domain enters cells by macropinocytosis 2005;J Control Release 2014;190:56-8
41. Imamura J, Suzuki Y, Gonda K, et al. Single particle tracking confirms that multivalent Tat protein transduction domain-induced heparan sulfate proteoglycan cross-linkage activates Rac1 for internalization. J Biol Chem 2011;286:10581-92
42. Lundberg M, Wikstrom S, Johansson M. Cell surface adherence and endocytosis of protein transduction domains. Mol Ther 2003;8:143-50
43. Yukawa H, Noguchi H, Nakase I, et al. Transduction of cell-penetrating peptides into induced pluripotent stem cells. Cell Transplant 2010;19:901-9
44. Khalil IA, Kogure K, Futaki S, Harashima H. High density of octaarginine stimulates macropinocytosis leading to efficient intracellular trafficking for gene expression. J Biol Chem 2006;281:3544-51
45. Andaloussi SEl, Guterstam P, Langel U. Assessing the delivery efficacy and internalization route of cell-penetrating peptides. Nat Protoc 2007;2:2043-7
46. El-Andaloussi S, Johansson HJ, Holm T, Langel U. A novel cell-penetrating peptide, M918, for efficient delivery of proteins and peptide nucleic acids. Mol Ther 2007;15:1820-6
47. Erazo-Oliveras A, Muthukrishnan N, Baker R, et al. Improving the endosomal escape of cell-penetrating peptides and their cargos: strategies and challenges. Pharmaceuticals (Basel) 2012;5:1177-209
48. Fuchs SM, Raines RT. Pathway for polyarginine entry into mammalian cells. Biochemistry 2004;43:2438-44
49. Skehel JJ, Cross K, Steinhauer D, Wiley DC. Influenza fusion peptides. Biochem Soc Trans 2001;29:623-6
50. Han X, Bushweller JH, Cafiso DS, Tamm LK. Membrane structure and fusion-triggering conformational change of the fusion domain from influenza hemagglutinin. Nat Struct Biol 2001;8:715-20
51. Akinc A, Thomas M, Klibanov AM, Langer R. Exploring polyethyleniminemediated DNA transfection and the proton sponge hypothesis. J Gene Med 2005;7:657-63
52. Lo SL, Wang S. An endosomolytic Tat peptide produced by incorporation of histidine and cysteine residues as a nonviral vector for DNA transfection. Biomaterials 2008;29:2408-14
53. Summerton JE. Endo-Porter: A novel reagent for safe, effective delivery of substances into cells. Ann N Y Acad Sci 2005;1058:62-75
54. El-Andaloussi S, Johansson HJ, Lundberg P, Langel U. Induction of splice correction by cell-penetrating peptide nucleic acids. J Gene Med 2006;8:1262-73
55. Andaloussi SEL, Lehto T, Mäger I, et al. Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo. Nucleic Acids Res 2011;39:3972-87
56. Peitz M, Münst B, Thummer RP, et al. Cell-permeant recombinant Nanog protein promotes pluripotency by inhibiting endodermal specification. Stem Cell Res 2014;12:680-9
57. Bosnali M, Edenhofer F. Generation of transducible versions of transcription factors Oct4 and Sox2. Biol Chem 2008;389:851-61
58. Amsellem S, Pflumio F, Bardinet D, et al. Ex vivo expansion of human hematopoietic stem cells by direct delivery of the HOXB4 homeoprotein. Nat Med 2003;9:1423-7
59. Toro A, Paiva M, Ackerley C, Grunebaum E. Intracellular delivery of purine nucleoside phosphorylase (PNP) fused to protein transduction domain corrects PNP deficiency in vitro. Cell Immunol 2006;240:107-15
60. Toro A, Grunebaum E. TAT-mediated intracellular delivery of purine nucleoside phosphorylase corrects its deficiency in mice. J Clin Invest 2006;116:2717-26
61. Tanaka S, Pero SC, Taguchi K, et al. Specific peptide ligand for Grb7 signal transduction protein and pancreatic cancer metastasis. J Natl Cancer Inst 2006;98:491-8
62. Snyder EL, Meade BR, Saenz CC, Dowdy SF. Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide. PLoS Biol 2004;2:E36
63. Boisguerin P, Redt-Clouet C, Franck-Miclo A, et al. Systemic delivery of BH4 anti-apoptotic peptide using CPPs prevents cardiac ischemiareperfusion injuries in vivo. J Control Release 2011;156:146-53
64. Bernatchez PN, Bauer PM, Yu J, et al. Dissecting the molecular control of endothelial NO synthase by caveolin-1 using cell-permeable peptides. Proc Natl Acad Sci USA 2005;102:761-6
65. Jo J, Hong S, Choi WY, Lee DR. Cell-penetrating peptide (CPP)-conjugated proteins is an efficient tool for manipulation of human mesenchymal stromal cells. Sci Rep 2014;4:4378
66. Hotchkiss RS, McConnell KW, Bullok K, et al. TAT-BH4 and TAT-Bcl-xL peptides protect against sepsis-induced lymphocyte apoptosis in vivo. J Immunol 2006;176:5471-7
67. Cao G, Pei W, Ge H, et al. In Vivo Delivery of a Bcl-xL Fusion Protein Containing the TAT Protein Transduction Domain Protects against Ischemic Brain Injury and Neuronal Apoptosis. J Neurosci 2002;22:5423-31
68. Kwon JH, Kim J-B, Lee KH, et al. Protective effect of heat shock protein 27 using protein transduction domainmediated delivery on ischemia/ reperfusion heart injury. Biochem Biophys Res Commun 2007;363:399-404
69. Eguchi A, Meade BR, Chang YC, et al. Efficient siRNA delivery into primary cells by a peptide transduction domaindsRNA binding domain fusion protein. Nat Biotechnol 2009;27:567-71
70. Meade BR, Gogoi K, Hamil AS, et al. Efficient delivery of RNAi prodrugs containing reversible charge-neutralizing phosphotriester backbone modifications. Nat Biotechnol 2014;32:1256-61
71. Abes S, Turner JJ, Ivanova GD, et al. Efficient splicing correction by PNA conjugation to an R6-Penetratin delivery peptide. Nucleic Acids Res 2007;35:4495-502
72. Turner JJ, Ivanova GD, Verbeure B, et al. Cell-penetrating peptide conjugates of peptide nucleic acids (PNA) as inhibitors of HIV-1 Tat-dependent transactivation in cells. Nucleic Acids Res 2005;33:6837-49
73. Nakase I, Tanaka G, Futaki S. Cell-penetrating peptides (CPPs) as a vector for the delivery of siRNAs into cells. Mol Biosyst 2013;9:855-61
74. Jiang T, Olson ES, Nguyen QT, et al. Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc Natl Acad Sci USA 2004;101:17867-72
75. MacEwan SR, Chilkoti A. Harnessing the power of cell-penetrating peptides: Activatable carriers for targeting systemic delivery of cancer therapeutics and imaging agents. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2013;5:31-48
76. Nguyen QT, Olson ES, Aguilera TA, et al. Surgery with molecular fluorescence imaging using activatable cell-penetrating peptides decreases residual cancer and improves survival. Proc Natl Acad Sci USA 2010;107:4317-22
77. Metildi CA, Felsen CN, Savariar EN, et al. Ratiometric Activatable Cell-Penetrating Peptides Label Pancreatic Cancer, Enabling Fluorescence-Guided Surgery, Which Reduces Metastases and Recurrence in Orthotopic Mouse Models. Ann Surg Oncol 2015;22:2082-87
78. Cardozo AK, Buchillier V, Mathieu M, et al. Cell-permeable peptides induce dose-and length-dependent cytotoxic effects. Biochim Biophys Acta 2007;1768:2222-34
79. Verdurmen WPR, Brock R. Biological responses towards cationic peptides and drug carriers. Trends Pharmacol Sci 2011;32:116-24
80. Suhorutsenko J, Oskolkov N, Arukuusk P, et al. Cell-penetrating peptides, PepFects, show no evidence of toxicity and immunogenicity in vitro and in vivo. Bioconjug Chem 2011;22:2255-62
81. Begley R, Liron T, Baryza J, Mochly-Rosen D. Biodistribution of intracellularly acting peptides conjugated reversibly to Tat. 2004;318(4):949-54
82. Aguilera TA, Olson ES, Timmers MM, et al. Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides. Integr Biol (Camb) 2009;1:371-81
83. Kaspar AA, Reichert JM. Future directions for peptide therapeutics development. Drug Discov Today 2013;18:807-17
84. Ghatnekar GS, O'Quinn MP, Jourdan LJ, et al. Connexin43 carboxylterminal peptides reduce scar progenitor and promote regenerative healing following skin wounding. Regen Med 2009;4:205-23
85. Ghatnekar GS, Grek CL, Armstrong DG, et al. The effect of a connexin43-based Peptide on the healing of chronic venous leg ulcers: A multicenter, randomized trial. J Invest Dermatol 2015;135:289-98